Recommendations for stroke management second part: Primary and secondary prevention of stroke;Preporuke za zbrinjavanje bolesnika s moždanim udarom drugi dio: Primaraa i sekundarna prevencija moždanog udara

Lijecnicki Vjesnik

Volumn 125, Issue 11-12, 2003, Pages 322-328

  Demarin, Vida ^a   Lovrenčić Huzjan, Arijana ^a   Šerić, Vesna ^a   Vargek Solter, Vesna ^a   Trkanjec, Zlatko ^a   Vuković, Vlasta ^a   Lupret, Velimir ^a   Kalousek, Miljenko ^a   Desyo, Drago ^a   Kadojić, Dragutin ^b   Lušić, Ivo ^c   Dikanović, Marinko ^d   Vitas, Marija ^e  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^c UNIVERSITY HOSPITAL SPLIT   (Croatia)

^d Opca bolnica Dr J Bencevic   (Croatia)

^e Odjel za Neurologiju   (Croatia)

Author keywords

Cerebrovascular accident prevention and control; Croatia; Neurology organization and administration; Practice guidelines

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

CEREBROVASCULAR ACCIDENT; CROATIA; DISEASE CONTROL; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE;

CEREBROVASCULAR ACCIDENT; HUMANS; PRIMARY PREVENTION; RISK FACTORS;

EID: 2542485367     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Demarin V, Rundek T, Tomljanović B, Carillo-Pintos J, Masso-Estrade J. Prevention of stroke - a report from collaboration project between Zagreb and Barcelona. Neurol Croat 1992;41:43-50.
2. Demarin V, Huzjan-Lovrenčić A, Bosnar M, Podobnik-Šarkanji S, Thaller N. Čimbenici rizika za razvoj ishemičnog moždanog udara. Liječ Vjesn 1999;(Supl.1):86.
3. Demarin V. Ključ za zdrave dane mozak i žile bez mane. 2. izd. Zagreb: Naprijed, 1995.
4. Demarin V. Zdravi stil življenja u prevenciji cerebrovaskularnih bolesti. U: Mirić D, Vlahović D (ur.). Zdravlje i turizam. Split - Hvar: Hrvatsko kardiološko društvo - ogranak Split i Turistic̀ka zajednica, 1998:295-301.
5. Lovrenčić-Huzjan A, Bosnar M, Huzjan R, Demarin V. Frequency of different risk factors for ischemic stroke. Acta clin Croat 1999;38:159-63.
6. Gillman MW, Cupples LA, Gagnon D, Posner BM, Ellison RC, Castelli WP, Wolf PA. Protective effect of fruits and vegetables on development of stroke in men. JAMA 1995;273:1113-7.
7. Lee I, Hennekens C, Berger K, Buring J, Manson J. Exercise and risk of stroke in male physicians. Stroke 1999;30:1-6.
8. Hodek-Demarin V, Blažić-Čop N, Hudolin Vi, Thaller N. Ocjena stanja cerebralne cirkulacije pušača. Anali KB «Dr. M. Stojanović» 1978;17:109-14.
9. Demarin V, Blažić-Čop N, Dordević V, Bošnjak M, Rundek T, Posavec V. Transcranial Doppler investigation in cigarette smokers. Arteries et Veines. 1991;10:113-9.
10. Abbott R, Yin Y, Reed D, Yano K. Risk of stroke in male cigarette smokers. N Engl J Med 1986;315:717-20.
11. Colditz G, Bonita R, Stampfer M, Willett W et al. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med 1988;318:937-41.
12. Sacco R, Elkind M, Boden-Albala B, Lin I et al. The protective effect of moderate alcohol consumption on ischaemic stroke. JAMA 1999;281:53-60.
13. Schenk MJ. Is psychological stress a risk factor for cerebrovascular disease? Neuroepidemiology 1997;16:174-9.
14. Manuck SB, Kaplan JR, Matthews KA. Behavioral antecedents of coronary heart disease and atherosclerosis. Atherosclerosis 1986;6:1-14.
15. Kamarck TW, Everson SA, Kaplan GA, Manuck SB, Jennings JR, Salonen R, Salonen JT. Exaggerated blood pressure responses during mental stress are associated with enhanced carotid atherosclerosis in middle-aged Finnish men. Findings from the Kuopio Ischemic Heart Disease Study. Circulation 1997;96:3841-8.
16. Demarin V, Podobnik-Šarkanji S, Lovrenčić-Huzjan A, Rundek T, Thaller N. Stress as a risk factor in the development of neurological diseases. Acta Clin Croat 1992;31:233-8.
17. Kleinman Y, Korn-Lubetzki I, Elaishiv S, Abramsky O, Eliakim M. High frequency of hemorrhagic strokes in Jerusalem during the Persian Gulf War. Neurology 1992;42:2225-6.
18. Dimitrijević J, Gavranović M, Džirlo K, Bratić M, Hrnjica M, Bulić G, Hebib LJ. Cerebrovascular accidents in Sarajevo during the war. Rev Neurol 1999;155:359-64.
19. Kadojić D, Demarin V, Kadojić M, Mihaljević I, Barac B. Influence of prolonged stress on risk factors for cerebrovascular disease. Coll Anthropol 1999;23:213-9.
20. Lušić I, Janković S, Andelinović Š. Incidence of stroke in central Dalmatia during the war in the Republic of Croatia. Rev Neurol 1999;29:23-6.
21. Dikanović M. Transcranial doppler sonography for post-traumatic stress disorder. Acta clin Croat 1999;38:294-8.
22. Kadojić D, Barac B. Stress as a triggering mechanism for the appearance of subarachnoid hemorrhage. Neuroepidemiology 2001;20:45-6.
23. Bousser MG, Kittner SJ. Oral contraceptives and stroke. Cephalalgia 2000;20:183-9.
24. Demarin V, Rajković D, Hodek B. Evaluation of Cerebral Circulation During Oral Contraceptives Taking. Medit J Soc Psychiatry. 1986;7:57-61.
25. Schwartz SM, Petitti DB, Sincovich DA, Longstreth WT Jr et al. Stroke and use of low-dose oral contraceptives in young women. A pooled analysis of two US studies. Stroke 1998;29:2277-84.
26. WHO Collaborative Study. Cardiovascular Disease, Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results ofan international, multicentre, case-control study. Lancet 1996;348:498-505.
27. WHO Collaborative Study. Cardiovascular Disease, Steroid Hormone, Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505-10.
28. Demarin V, Lovrenčić-Huzjan A. Estrogen replacement therapy: a review of its potential benefits in neurology. Acta clin Croat 1998;37:201-6.
29. Kittner SJ, Bousser MG. Post-menopausal hormone replacement therapy and stroke risk. Cephalalgia 2000;20:208-13.
30. Pentz Vuković I, Demarin V, Grubišić G, Kuna K. Lovrenčić Huzjan A. Carotid artery intima thickness and flow velocity after discontinuation of hormone replacement therapy in postmenopausal women:follow-up study. Croat Med J 2001;42:54-7.
31. Demarin V. Učinak hormonskog nadomjesnog liječenja u neurologiji. Drugi hrvatski konsenzus o hormonskom nadomjesnom liječenju u klimakteriju i postmenopauzi. Poreč: Drugi hrvatski konsenzus o hormonskom nadomjesnom liječenju u klimakteriju i postmenopauzi, 1998:35-40.
32. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-42.
33. Levine SR, Brust JC, Futrell N, Ho KL et al. Cerebrovascular complications of the use of the 'crack' form of alkaloidal cocaine. N Engl J Med 1990;323:699-704.
34. Collins R, Peto P, MacMahon S, Herbert P, Fiebach N, Eberlein K. Blood pressure, stroke, and coronary heart disease. 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
35. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;365:3255-64.
36. SHEP Cooperative Research Group. Prevention of various stroke types by treatment of isolated systolic hypertension. Presented at: International Stroke Society's Second World Congress of Stroke; Washington, DC; September 1992.
37. The HOPE Investigators: Effects ofan ACE inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
38. PROGRESS Collaborative Group: Randomised trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke of transient ishaemic attack. Lancet 2001;358:1033-41.
39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
40. Prospective Studies Collaboration: Cholesterol, diastolic blood pressure and stroke. 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995;346:1647-53.
41. Shepherd J, Cobbe S, Ford I, Isles C et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
42. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
43. Plehn J, Davis B, Sacks F, Rouleau J et al. Reduction of stroke incidence after myocardial infarction with pravastatin: The cholesterol and recurrent events (CARE) study. Circulation 1999;99:216-33.
44. Pedersen TR, Kjeshus O, Pyorala K, Olsson AG et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-5.
45. Blaw G, Lagaay A, Smelt A, Westendorp R. Stroke, statins and cholesterol. A meta-analysis of randomised, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-50.
46. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
47. Peto R, Gray R, Collins R, Wheatley K et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313-6.
48. Steering Committee of the Physician's Health Study Research Group. Final report of the ongoing physicians health study. N Engl J Med 1989;321:129-35.
49. Manson J, Stampfer M, Colditz G, Willett W et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521-7.
50. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study (ACAS). Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-8.
51. North American Symptomatic Carotid Endarterectomy Trial Collaborators (NASCET). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-53.
52. European Carotid Surgery Trialists Collaborative Group. MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-90%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-43.
53. Qureshi AD, Janardhan V, Bennet SE, Luft AR, Hopkins LN, Guterman LR. Who should be screened for asymptomatic carotid artery stenosis? Experience from the Western New York Stroke Screening Program. J Neuroimaging 2001;11:105-11.
54. Hacke W, Kaste M, Skyhoj Olsen T, Orgogozo J-M, Bogousslavsky J. European Stroke Initiative (EUSI) Recommendations for Stroke Management. The European Stroke Initiative Writing Committee. Europ J Neurol 2000;7:607-23.
55. Laupacis A, Albers G, Dalen J, Dunn M, Jacobson A, Singer D. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579-89.
56. European Atrial Fibrillation Study Group. Optimal oral anticoagulation therapy with nonrheumatic atrial fibrillation and recent cerebral ischaemia. N Engl J Med 1995;333:5-10.
57. Hart R, Sherman D, Easton D, Cairnes J. Prevention of stroke in patients with nonvalvular atrial fibrillation: Views and reviews. Neurology 1998;51:674-81.
58. Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-52.
59. Bogousslavsky J (ed). Stroke prevention by the practitioner. Cerebrovasc Dis 1999;(Suppl 4):9.
60. Trkanjec Z, Demarin V. Antiplatelet therapy in secondary prevention of stroke. Acta clin Croat 1999;38(Suppl I):41-3.
61. Demarin V. Moždani udar - priručnik za bolesnike i članove njihove obitelji. Koprivnica: Belupo, 2001.
62. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
63. SALT collaborative group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;228:1345-9.
64. Patrono C, Roth GJ. Aspirin in ischemic cerebrovascular disease. Stroke 1996;27:756-60.
65. Dyken ML, Barnett HJM, Easton JD et al. Low-dose aspirin and stroke: »It ain't necessarily so«. Stroke 1992;23:1395-9.
66. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or a minor stroke. N Engl J Med 1991;325:1261-6.
67. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
68. Diener HC, Cunha L, Forbes C, Silvenius J, Smets P, Lowenthal A. European stroke prevention study 2, dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
69. Diener HC. Stroke prevention. Antiplatelet and antithrombolytic therapy. Neurol Clinics 2000;19:343-55.
70. Gent M, Blakely JA, Easton JD et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
71. Hass WK, Easton JD, Adams HP et al. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk individuals. N Engl J Med 1989;321:501-7.
72. Bennett CL, Kiss JE, Weinberg PD et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 1998;325:1036-37.
73. Page Y, Tardy B, Zeny F et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lance 1991;1:774-6.
74. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39.
75. Bennett CL, Connors JM, Carwile JM et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-7.
76. Ringleb PA, Bertram M, Keller E, Hacke W. Hypertension in patients with cerebrovascular accidents, To treat or not to treat? Nephrol Dial Transplant 1998;13:2179-281.
77. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1998;114(Suppl):470S-88S.
78. American-Canadian Co-operative Study Group. Persantine-Aspirin in cerebral ischemia, part II: Endpoint results. Stroke 1985;16:406-15.
79. Bousser MG, Eschwege E, Haguenau M et al. «A.I.C.L.A»: controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1983;13:5-14.
80. Guiraud-Chaumeil B, Rascol A, David J et al. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires. Rev Neurol (Paris) 1982;138:367-85.
81. Cannegiester S, Rosendaal F, Witzen A, Van Der Meer F, Vandenbroucke J, Briët E. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
82. Barnnett H, Taylor W, Eliasziw M, Fox A, Ferguson G, Haynes R et al. Benefit of endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-25.
83. Yadav J, Roubin G, King P, Ivery S, Vitek J. Angioplasty and stenting for restenosis after carotid endarterectomy, initial experience. Stroke 1996;27:2975-9.
84. CAVATAS investigators. Endovascular surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001;357:1729-37.